The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

Volume: 44, Issue: 6, Pages: 711 - 722
Published: May 27, 2021
Abstract
Upadacitinib is a Janus kinase inhibitor with demonstrated efficacy in patients with rheumatoid arthritis (RA).The aim of this study was to assess the long-term safety of upadacitinib in patients with active RA from Japan compared with global clinical trial populations.Pooled data in patients enrolled from Japan (the 'Japanese population'; SELECT-SUNRISE, SELECT-EARLY, and SELECT-MONOTHERAPY) were compared with that from global (Japan and...
Paper Details
Title
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
Published Date
May 27, 2021
Volume
44
Issue
6
Pages
711 - 722
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.